Positron emission tomography applications in clinical neurology

Seminars in Neurology

Volumn 32, Issue 4, 2012, Pages 421-431

  Singhal, Tarun ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

brain tumors; dementia; epilepsy; movement disorders; neurology; positron emission tomography (PET)

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; 3 (2 AZETIDINYLMETHOXY)PYRIDINE C 11; 6 FLUORODOPA F 18; CARFENTANIL C 11; CARMUSTINE C 11; DIPRENORPHINE C 11; FBL 457 C 11; FLUMAZENIL C 11; FLUORODEOXYGLUCOSE F 18; LEUCINE C 11; MCNEIL 5652 C 11; MDL 100907 C 11; METHIONINE C 11; METHYL SPIPERONE C 11; MP4A C 11; MTBZ C 11; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE C 11; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; NOMIFENSINE C 11; OXYGEN 15; PRENYL C 11; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; SCHERING 23390 C 11; TRACER; TYROSINE C 11; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL C 11; WATER O 15;

ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; BRAIN INFECTION; BRAIN TUMOR; CLINICAL PRACTICE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; ENCEPHALITIS; EPILEPSY; FRONTOTEMPORAL DEMENTIA; IMAGE ANALYSIS; ISOTOPE LABELING; MOTOR DYSFUNCTION; MULTIINFARCT DEMENTIA; NEUROLOGY; NEUROPATHOLOGY; NEUROPSYCHIATRY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BRAIN NEOPLASMS; DEMENTIA; EPILEPSY; HUMANS; INFLAMMATION; MOVEMENT DISORDERS; NERVOUS SYSTEM DISEASES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84872960348     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0032-1331813     Document Type: Article

References (63)

1. Phelps M. E. PET: a biological imaging technique. Neurochem Res: 1991; 16 9 929 940
2. James M. L., Gambhir S. S. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev: 2012; 92 2 897 965
3. Jones T., Rabiner E. A. PET Research Advisory Company The development, past achievements, and future directions of brain PET. J Cereb Blood Flow Metab: 2012; 32 7 1426 1454
4. Minoshima S., Frey K. A., Koeppe R. A., Foster N. L., Kuhl D. E. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med: 1995; 36 7 1238 1248
5. Friston K. J. Commentary and opinion: II. Statistical parametric mapping: ontology and current issues. J Cereb Blood Flow Metab: 1995; 15 3 361 370
6. Signorini M., Paulesu E., Friston K., et al. Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: A clinical validation of statistical parametric mapping. Neuroimage: 1999; 9 1 63 80 (Pubitemid 29369342)
7. Tang C. C., Poston K. L., Eckert T., et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol: 2010; 9 2 149 158
8. Eckert T., Tang C., Eidelberg D. Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol: 2007; 6 10 926 932 (Pubitemid 47405003)
9. Minoshima S., Giordani B., Berent S., Frey K. A., Foster N. L., Kuhl D. E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol: 1997; 42 1 85 94 (Pubitemid 27304784)
10. Silverman D. H., Small G. W., Chang C. Y., et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA: 2001; 286 17 2120 2127 (Pubitemid 34041597)
11. Herholz K., Heiss W. D. Positron emission tomography in clinical neurology. Mol Imaging Biol: 2004; 6 4 239 269 (Pubitemid 39022761)
12. Rabinovici G. D., Rosen H. J., Alkalay A., et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology: 2011; 77 23 2034 2042
13. Gilman S., Koeppe R. A., Little R., et al. Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol: 2005; 191 01 S95 S103 (Pubitemid 40081108)
14. Sultzer D. L., Mahler M. E., Cummings J. L., Van Gorp W. G., Hinkin C. H., Brown C. Cortical abnormalities associated with subcortical lesions in vascular dementia. Clinical and position emission tomographic findings. Arch Neurol: 1995; 52 8 773 780
15. Zhang S., Han D., Tan X., Feng J., Guo Y., Ding Y. Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment. Int J Clin Pract: 2012; 66 2 185 198
16. Klunk W. E., Engler H., Nordberg A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol: 2004; 55 3 306 319 (Pubitemid 38269583)
17. Rowe C. C., Villemagne V. L. Brain amyloid imaging. J Nucl Med: 2011; 52 11 1733 1740
18. Clark C. M., Pontecorvo M. J., Beach T. G., et al. AV-45-A16 Study Group Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol: 2012; 11 8 669 678
19. Okello A., Koivunen J., Edison P., et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology: 2009; 73 10 754 760
20. Gilman S., Koeppe R. A., Junck L., Kluin K. J., Lohman M., St Laurent R. T. Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy. Ann Neurol: 1994; 36 2 166 175 (Pubitemid 24239233)
21. Bohnen N. I., Frey K. A. The role of positron emission tomography imaging in movement disorders. Neuroimaging Clin N Am: 2003; 13 4 791 803 (Pubitemid 37445056)
22. Sperling M. R. Neuroimaging in epilepsy: contribution of MRI, PET and SPECT. Semin Neurol: 1990; 10 4 349 356
23. Steele J. C., Richardson J. C., Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol: 1964; 10 333 359
24. Foster N. L., Gilman S., Berent S., Morin E. M., Brown M. B., Koeppe R. A. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol: 1988; 24 3 399 406
25. Brooks D. J., Seppi K. Neuroimaging Working Group on MSA Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord: 2009; 24 7 949 964
26. Brooks D. J. Can imaging separate multiple system atrophy from Parkinson's disease? Mov Disord: 2012; 27 1 3 5
27. Hosokawa S., Ichiya Y., Kuwabara Y., et al. Positron emission tomography in cases of chorea with different underlying diseases. J Neurol Neurosurg Psychiatry: 1987; 50 10 1284 1287 (Pubitemid 17150698)
28. Gilman S., Frey K. A., Koeppe R. A., et al. Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography. Ann Neurol: 1996; 40 6 885 892 (Pubitemid 27044606)
29. Eidelberg D., Moeller J. R., Dhawan V., et al. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord: 1990; 5 3 203 213 (Pubitemid 20311769)
30. Koeppe R. A., Gilman S., Junck L., Wernette K., Frey K. A. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. Alzheimers Dement: 2008; 4 1 01 S67 S76
31. Lin K. J., Lin W. Y., Hsieh C. J., et al. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements. Nucl Med Biol: 2011; 38 8 1149 1155
32. Kupsch A., Bajaj N., Weiland F., et al. Changes in clinical management and diagnosis following DaTscan SPECT imaging in patients with clinically uncertain parkinsonian syndromes: a 12-week follow-up study. Neurodegener Dis: 2013; 11 1 22 32
33. Brooks D. J., Ibanez V., Sawle G. V., et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol: 1992; 31 2 184 192
34. Stoessl A. J., Brooks D. J., Eidelberg D. Milestones in neuroimaging. Mov Disord: 2011; 26 6 868 978
35. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci: 2009; 32 10 548 557
36. Burke J. F., Albin R. L., Koeppe R. A., et al. Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain: 2011; 134 Pt 6 1647 1657
37. Gomperts S. N., Rentz D. M., Moran E., et al. Imaging amyloid deposition in Lewy body diseases. Neurology: 2008; 71 12 903 910
38. Kim Y. K., Lee D. S., Lee S. K., et al. Differential features of metabolic abnormalities between medial and lateral temporal lobe epilepsy: quantitative analysis of (18)F-FDG PET using SPM. J Nucl Med: 2003; 44 7 1006 1012
39. Casse R., Rowe C. C., Newton M., Berlangieri S. U., Scott A. M. Positron emission tomography and epilepsy. Mol Imaging Biol: 2002; 4 5 338 351 (Pubitemid 36054800)
40. Luat A. F., Chugani H. T. Molecular and diffusion tensor imaging of epileptic networks. Epilepsia: 2008; 49 03 15 22 (Pubitemid 351317190)
41. 11C]-methyl-L- tryptophan PET for tracer localization of epileptogenic brain regions: clinical studies. Biomarkers Med: 2011; 5 5 577 584
42. Laufs H., Richardson M. P., Salek-Haddadi A., et al. Converging PET and fMRI evidence for a common area involved in human focal epilepsies. Neurology: 2011; 77 9 904 910
43. Love C., Tomas M. B., Tronco G. G., Palestro C. J. FDG PET of infection and inflammation. Radiographics: 2005; 25 5 1357 1368 (Pubitemid 41695350)
44. Hubele F., Bilger K., Kremer S., Imperiale A., Lioure B., Namer I. J. Sequential FDG PET and MRI findings in a case of human herpes virus 6 limbic encephalitis. Clin Nucl Med: 2012; 37 7 716 717
45. Leypoldt F., Buchert R., Kleiter I., et al. Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease. J Neurol Neurosurg Psychiatry: 2012; 83 7 681 686
46. Ances B. M., Vitaliani R., Taylor R. A., et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain: 2005; 128 Pt 8 1764 1777 (Pubitemid 41373648)
47. Darnell R. B., Posner J. B. A new cause of limbic encephalopathy. Brain: 2005; 128 Pt 8 1745 1746 (Pubitemid 41373646)
48. Cash S. S., Larvie M., Dalmau J. Case records of the Massachusetts General Hospital. Case 34-2011: A 75-year-old man with memory loss and partial seizures. N Engl J Med: 2011; 365 19 1825 1833
49. McKeon A., Apiwattanakul M., Lachance D. H., et al. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. Arch Neurol: 2010; 67 3 322 329
50. Dubey N., Miletich R. S., Wasay M., Mechtler L. L., Bakshi R. Role of fluorodeoxyglucose positron emission tomography in the diagnosis of neurosarcoidosis. J Neurol Sci: 2002; 205 1 77 81 (Pubitemid 36158997)
51. Ng D., Jacobs M., Mantil J. Combined C-11 methionine and F-18 FDG PET imaging in a case of neurosarcoidosis. Clin Nucl Med: 2006; 31 7 373 375 (Pubitemid 44315513)
52. Calabresi P. A., Bohnen N. I. Can PET imaging tell us what's the matter with the gray matter in multiple sclerosis? Neurology: 2012; 79 6 496 497
53. Kosaka N., Tsuchida T., Uematsu H., Kimura H., Okazawa H., Itoh H. H18F-FDG PET of common enhancing malignant brain tumors. AJR Am J Roentgenol: 2008; 190 6 W365-9 (Pubitemid 351798559)
54. Petrirena G. J., Goldman S., Delattre J. Y. Advances in PET imaging of brain tumors: a referring physician's perspective. Curr Opin Oncol: 2011; 23 6 617 623
55. Singhal T., Narayanan T. K., Jain V., Mukherjee J., Mantil J. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol: 2008; 10 1 1 18
56. Padma M. V., Said S., Jacobs M., et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol: 2003; 64 3 227 237 (Pubitemid 37203463)
57. Voges J., Herholz K., Hölzer T., et al. 11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotact Funct Neurosurg: 1997; 69 1-4 Pt 2 129 135
58. Miwa K., Shinoda J., Yano H., et al. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry: 2004; 75 10 1457 1462 (Pubitemid 39279817)
59. Pauleit D., Floeth F., Hamacher K., et al. O-(2-[18F]fluoroethyl)-L- tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain: 2005; 128 Pt 3 678 687 (Pubitemid 40380202)
60. Ackerman R. H., Correia J. A., Alpert N. M., et al. Positron imaging in ischemic stroke disease using compounds labeled with oxygen 15. Initial results of clinicophysiologic correlations. Arch Neurol: 1981; 38 9 537 543 (Pubitemid 11061653)
61. Tfelt-Hansen P. C., Koehler P. J. One hundred years of migraine research: major clinical and scientific observations from 1910 to 2010. Headache: 2011; 51 5 752 778
62. Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging: 1997; 18 4 351 357 (Pubitemid 27435070)
63. Feigin A., Tang C., Ma Y., et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain: 2007; 130 Pt 11 2858 2867 (Pubitemid 350033965)